FDA Approves Higher-Dose Tablet of Brigatinib for NSCLC

October 3, 2017 – The FDA has approved a supplemental new drug application for the use of 180-mg tablets of brigatinib for the treatment of patients with non–small cell lung cancer (NSCLC). In April 2017, the FDA granted an accelerated approval to brigatinib as a treatment for patients with metastatic ALK-positive NSCLC who are resistant to prior crizotinib. Brigatinib is approved at a starting dose of 90 mg once daily for 7 days. Patients who tolerate the initial regimen have … (leggi tutto)